Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025
Agios Pharmaceuticals (Nasdaq: AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has scheduled its first quarter 2025 financial results conference call and webcast for May 1, 2025, at 8:00 a.m. ET. The event will cover Q1 2025 financial performance and business updates.
The webcast will be available through the Investors section of Agios' website under Events & Presentations, with a replay accessible approximately two hours after the event.
Agios Pharmaceuticals (Nasdaq: AGIO), un'azienda specializzata in terapie per il metabolismo cellulare e l'attivazione della piruvato chinasi per malattie rare, ha programmato la conferenza telefonica e la webcast per la presentazione dei risultati finanziari del primo trimestre 2025 per il 1° maggio 2025 alle 8:00 ET. L'evento illustrerà le performance finanziarie del primo trimestre 2025 e gli aggiornamenti aziendali.
La webcast sarà disponibile nella sezione Investitori del sito web di Agios, sotto Eventi e Presentazioni, con la possibilità di rivederla circa due ore dopo la conclusione dell'evento.
Agios Pharmaceuticals (Nasdaq: AGIO), una empresa enfocada en terapias para el metabolismo celular y activación de la piruvato quinasa para enfermedades raras, ha programado su llamada y webcast para resultados financieros del primer trimestre de 2025 el 1 de mayo de 2025 a las 8:00 a.m. ET. El evento cubrirá el desempeño financiero del primer trimestre de 2025 y actualizaciones comerciales.
El webcast estará disponible en la sección de Inversores del sitio web de Agios, bajo Eventos y Presentaciones, con una repetición accesible aproximadamente dos horas después del evento.
Agios Pharmaceuticals (나스닥: AGIO)는 희귀 질환을 위한 세포 대사 및 피루브산 키나제 활성화 치료에 중점을 둔 회사로, 2025년 1분기 재무 결과 컨퍼런스 콜 및 웹캐스트를 2025년 5월 1일 오전 8시(동부시간)에 예정했습니다. 이번 행사는 2025년 1분기 재무 성과와 사업 업데이트를 다룰 예정입니다.
웹캐스트는 Agios 웹사이트의 투자자 섹션 내 이벤트 및 프레젠테이션에서 시청할 수 있으며, 행사 약 2시간 후 다시보기 서비스가 제공됩니다.
Agios Pharmaceuticals (Nasdaq : AGIO), une entreprise spécialisée dans les thérapies ciblant le métabolisme cellulaire et l’activation de la pyruvate kinase pour les maladies rares, a programmé sa conférence téléphonique et son webcast des résultats financiers du premier trimestre 2025 pour le 1er mai 2025 à 8h00 ET. L’événement couvrira la performance financière du premier trimestre 2025 ainsi que les mises à jour commerciales.
Le webcast sera accessible via la section Investisseurs du site web d’Agios, sous Événements & Présentations, avec un replay disponible environ deux heures après l’événement.
Agios Pharmaceuticals (Nasdaq: AGIO), ein Unternehmen, das sich auf Zellstoffwechsel und Pyruvatkinase-Aktivierungstherapien für seltene Krankheiten spezialisiert hat, hat seine Telefonkonferenz und Webcast zu den Finanzergebnissen des ersten Quartals 2025 für den 1. Mai 2025 um 8:00 Uhr ET angesetzt. Die Veranstaltung wird die finanzielle Leistung des ersten Quartals 2025 sowie geschäftliche Updates behandeln.
Der Webcast ist im Investor-Bereich der Agios-Website unter Veranstaltungen & Präsentationen verfügbar, mit einer Wiederholung, die etwa zwei Stunden nach der Veranstaltung abrufbar ist.
- None.
- None.
CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET to report its first quarter 2025 financial results and business highlights.
The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.
About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.
Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com
Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com
FAQ
When will Agios Pharmaceuticals (AGIO) release Q1 2025 earnings?
How can investors access Agios Pharmaceuticals' Q1 2025 earnings call?
Will there be a replay available for Agios' Q1 2025 earnings webcast?
What will Agios Pharmaceuticals discuss in their Q1 2025 earnings call?
